Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation

Abstract

Obinutuzumab (also known as GA101, afutuzumab, Gazyva) is a humanized, glycoengineered type II monoclonal antibody targeted against CD20. The US Food and Drug Administration has approved obinutuzumab for use with chlorambucil in patients with previously untreated chronic lymphocytic leukemia. The drug is the first treatment to receive approval under the agency's breakthrough therapy designation, a program intended to facilitate and expedite the review and development of therapies for serious and life-threatening conditions. In preclinical studies, obinutuzumab has showed superior efficacy, as compared with rituximab, by inducing direct cell death and increased antibody-dependent cellular cytotoxicity activity with less complement-dependent cytotoxicity. Regulatory approval of obinutuzumab is based on a phase III (CLL11) study that demonstrated improved outcomes with a combination of obinutuzumab with chlorambucil in previously untreated patients with chronic lymphocytic leukemia and comorbidities. Obinutuzumab plus chlorambucil induced deeper and longer remissions than rituximab plus chlorambucil combination as evidenced by prolongation of progression-free survival and higher complete response and molecular response rates. Marketing applications for obinutuzumab have also been submitted to other regulatory authorities including the European Medicines Agency.

Keywords

Chronic Lymphocytic Leukemia Obinutuzumab Anti-CD20 Breakthrough therapy Designation

Get full access to this article

View all access options for this article.

References

Altekruse

Kosari

Krapcho

. SEER clinical statistics review, 1975–2007, Bethesda, MD: National Cancer Institute, 2010.

Press Announcements – FDA approves Gazyva for chronic lymphocytic leukemia, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373209.htm (accessed 15 Nov 2013).

FDA, Dept. of Health & Human Services, Guidance for Industry: expedited programs for serious conditions- drugs and biologics, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf (accessed 30 Nov 2013).

EMA. Guideline on the procedure for accelerated assessment pursuant to Article 14 (9) of regulation (EC) No 726/2004, http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004136.pdf (accessed 25 Mar 2014).

EMA. Guideline on the scientific application and the practical arrangements necessary to implement commission regulation (EC) No 507/2006 on the conditional marketing authorisation for Medicinal products for human use falling within the scope of Regulation (EC) No 726/2004, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004908.pdf (accessed 26 Mar 2014).

Horning

Haber

Selig

WKD

. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013; 19: 4297–4304.

EMA. Parallel scientific advice with the Food and Drug Administration, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000049.jsp&mid=WC0b01ac05800229b9 (accessed 26 Mar 2014).

Mössner

Brünker

Moser

. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393–4402.

Niederfellner

Lammens

Mundigl

. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118: 358–367.

10.

US FDA. Clinical Review BLA 125486/0, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125486Orig1s000MedR.pdf (accessed 30 Nov 2013).

11.

Goede V. Head-To-Head Comparison of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb in Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage II Results of the CLL11 Trial, https://ash.confex.com/ash/2013/webprogram/Paper60276.html (2013, accessed 18 Dec 2013).

12.

Gazyva (obinutuzumab): US prescribing information, http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2013/125486s000lbl.pdf (2013, accessed 11 Dec 2013).

13.

US FDA. Clinical Pharmacology Secondary Review of Gazyva, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125486Orig1s000ClinPharmR.pdf (accessed 12 Dec 2013).

14.

Red Book Online, http://www.redbook.com/redbook/online (accessed 27 Mar 2014).

15.

Walzer

Becker

Samanta

. The potential cost-effectiveness of obinutuzumab (Ga101) in combination with chlorambucil in chronic lymphocytic leukemia. Value Health 2013; 16: A412–A412.